Coumestrol dimethyl ether

Other Names

3,9-Di-O-methylcoumesterol3,9-Di-O-methylcoumestrol3,9-dimethoxy-6H-benzofuro[3,2-c]chromen-6-one3,9-Dimethoxy-6H-benzofuro[3,2-c][1]benzopyran-6-one6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dimethoxy-7,12-Dimethoxy-coumestan

Synopsis

Coumestrol Dimethyl Ether

Identity and Chemical Characterization

Names, Classification, and Molecular Structure

Coumestrol dimethyl ether carries the IUPAC name 3,9-dimethoxy-6H-benzofuro[3,2-c]chromen-6-one, and is registered under CAS number 3172-99-4, with the molecular formula C₁₇H₁₂O₅ and a molecular weight of 296.28 g/mol. It is also known by the synonym 7,12-Dimethoxy-coumestan. The compound is classified under the category of coumestans, which are a type of phytoestrogen found in various plants. It is structurally related to coumestrol, a phytoestrogen, but is modified with two methoxy groups, a modification that typically alters the compound's physicochemical properties and can affect its interaction with biological molecules.

Coumestrol dimethyl ether (CDE) is the O-methylated derivative of the potent phytoestrogen coumestrol. While the parent compound coumestrol is a documented hydroxyl radical scavenger due to its free phenolic hydroxyl groups at C7 and C12, CDE lacks these primary donor sites. CDE is inherently fluorescent, with excitation at approximately 340–360 nm and emission at approximately 420–460 nm.

Relationship to the Parent Compound: Coumestrol

Coumestrol is a natural organic compound in the class of phytochemicals known as coumestans. It was first identified as a compound with estrogenic properties by E. M. Bickoff in ladino clover and alfalfa in 1957. Coumestrol (3,9-dihydroxy-6-benzofuran[3,2-c]chromenone) as a phytoestrogen and polyphenolic compound is a member of the coumestans family and is quite common in plants. In the dimethyl ether derivative, the two hydroxyl groups at positions 3 and 9 of the coumestan ring are replaced by methoxy groups (–OCH₃), distinguishing it from both coumestrol itself and from the diacetate ester analog.

Natural Occurrence and Botanical Sources

Coumestrol dimethyl ether is a natural product found in Dalbergia decipularis and Bobgunnia madagascariensis. Bobgunnia madagascariensis, known in Bambara as "samagara" and also called the snake bean plant, is a species of legume in the family Fabaceae. It is a small deciduous tree, 3–4 m tall. Both source plants belong to the family Fabaceae (legumes). The parent compound coumestrol is more broadly distributed: the main dietary source of coumestrol is legumes; however, low levels have been reported in Brussels sprouts and spinach. Clover and soybean sprouts are reported to have the highest concentration, 28 and 7 mg/100 g dry weight, respectively; mature soybeans contain only about 0.12 mg/100 g dry weight.

Coumestrol is one of the phytoestrogens and is usually found in the seed, root or leaf of plants in the family Leguminosae or Compositae. Levels of coumestrol within individual plants of the same species are variable. Studies of coumestrol levels in alfalfa suggest that there may be a positive correlation between coumestrol production and infection of the plant by viruses, bacteria, and fungi.

Common Forms and Preparations

In commercial and research contexts, coumestrol dimethyl ether is available primarily as a purified solid reagent. It is supplied as a BioReagent suitable for fluorescence studies, with purity ≥95% by HPLC. It can be synthesized through several methods: methylation of coumestrol using methylating agents such as dimethyl sulfate or methyl iodide in the presence of a base; chemical modification of natural sources by extracting coumestrol from plant sources followed by selective methylation; or total synthesis via advanced multi-step synthetic routes from simpler organic compounds. It is not currently formulated as a standalone dietary supplement in any standard commercial product and does not appear in any approved pharmacopeial monograph.

Traditional and Historical Use

Coumestrol dimethyl ether as a distinct isolated compound has no documented history of traditional or ethnobotanical use. Traditional medicine traditions did not isolate or characterize individual phytochemicals; use was always in the form of whole plant or crude preparations. The relevant traditional history, therefore, belongs to the source plants and to coumestrol-containing botanicals more broadly.

Coumestrol was first identified as a compound with estrogenic properties in ladino clover and alfalfa in 1957. The recognition of estrogenic effects in plants preceded this by decades: recognition of the endocrine-disrupting properties of phytoestrogens dates back to the 1940s, when ewes grazing on clover-rich pastures in Australia were observed to have abnormally high rates of infertility, abortion, and reproductive abnormalities in their offspring. It was ultimately determined that coumestrol was primarily responsible for these observed effects.

Phytoestrogens are naturally occurring plant compounds that have oestrogenic and/or anti-oestrogenic activity. They are present in many human foodstuffs including beans, sprouts, cabbage, spinach, soybean, grains and hops. The main classes are the isoflavones, coumestans and lignans. Coumestrol has garnered research interest because of its estrogenic activity and prevalence in some foods, including soybeans, Brussels sprouts, spinach and a variety of legumes. Plants bearing these compounds were used across multiple cultures as foods and medicinal preparations. However, claims that coumestrol dimethyl ether specifically was a target of historical use are not supported by primary historical or ethnobotanical sources, and such assertions found on supplement-brand websites cannot be verified against peer-reviewed literature.

Key Constituents and Active Compounds

The Coumestan Scaffold

There is increasing attention in the medicinal potential of coumestans, particularly coumestrol, wedelolactone, psoralidin and glycyrol, in a variety of diseases. A comprehensive review of coumestans isolated from various plant sources during the period 1956–2020 documented 120 molecules, which showed a wide range of pharmacological activities including estrogenic, anti-cancer, anti-inflammatory, anti-osteoporotic, organ protective, neuroprotective, anti-diabetic and anti-obesity, antimicrobial, immunosuppressive, antioxidant and skin-protective activities.

Structural Basis of Activity: Comparison with Coumestrol

The presence of two hydroxyl groups on coumestrol's chemical structure, with orientation analogous to estradiol, is responsible for both its antioxidant capacity and its estrogenic activity. The chemical shape of coumestrol orients its two hydroxy groups in the same position as the two hydroxy groups in estradiol, allowing it to inhibit the activity of aromatase and 3α-hydroxysteroid dehydrogenase. These enzymes are involved in the biosynthesis of steroid hormones, and inhibition of these enzymes results in interference with hormone metabolism.

In coumestrol dimethyl ether, these hydroxyl groups are replaced by methoxy groups. Coumestrol exhibits high antioxidant activity via hydrogen atom transfer (HAT) from its –OH groups. In coumestrol dimethyl ether, the methylation of the 7,12-hydroxyls blocks this HAT mechanism. Consequently, CDE will likely show negligible activity in cell-free assays such as DPPH or ABTS. Unlike standard polyphenols, CDE's potential value lies not in direct radical scavenging, but in its lipophilicity, metabolic stability, and potential as a pro-drug or indirect Nrf2 activator.

Fluorescence Properties

Both coumestrol and its dimethyl ether are inherently fluorescent, a property that has been extensively exploited in biochemical research. Coumestrol has been studied as an inherently fluorescent analog of 17β-estradiol, and its binding to, and dissociation from, the human estrogen receptor can be directly determined by the change in fluorescence intensity of the probe. Coumestrol emits intense blue fluorescence when bound to the estrogen receptor, making it ideally suited for use as a cytological stain to detect ER in fixed and intact cells. The dimethyl ether retains this fluorescent characteristic. CDE is inherently fluorescent (excitation ~340–360 nm; emission ~420–460 nm), a spectral property that overlaps with common oxidative stress probes such as DCFDA and DHE, necessitating strict background subtraction protocols in experimental work.

Mechanisms of Action

Estrogen Receptor Interactions

Coumestrol is a phytoestrogen that mimics the biological activity of estrogens. Phytoestrogens are able to pass through cell membranes due to their low molecular weight and stable structure, and they are able to interact with the enzymes and receptors of cells. Coumestrol binds to ERα and ERβ with similar affinity to that of estradiol (94% and 185% of the relative binding affinity of estradiol at ERα and ERβ, respectively), although the estrogenic activity of coumestrol at both receptors is much less than that of estradiol. In any case, coumestrol has estrogenic activity that is 30 to 100 times greater than that of isoflavones.

The dimethyl ether derivative, by contrast, has substantially altered receptor-binding behavior. The methylation of coumestrol dimethyl ether typically alters the compound's physicochemical properties and can affect its interaction with biological molecules. In research studies, it is utilized to understand the impact of structural modifications on the binding affinity and selectivity of compounds to estrogen receptors. It also serves as a model compound for the synthesis of more complex molecules that mimic or interfere with the action of naturally occurring estrogens. Crucially, because the free hydroxyl groups critical for high-affinity estrogen receptor binding are blocked, coumestrol dimethyl ether is expected to have markedly reduced estrogenic activity compared to coumestrol itself.

Pregnane X Receptor (PXR) Interactions

The most extensively studied receptor-level activity relevant to coumestrol dimethyl ether involves the Pregnane X Receptor. The pregnane X receptor (PXR, NR1I2) is a xenobiotic-activated transcription factor with high levels of expression in the liver. It not only plays a key role in drug metabolism and elimination, but also promotes tumor growth, drug resistance, and metabolic diseases. It has been proposed as a therapeutic target for type II diabetes, metabolic syndrome, and inflammatory bowel disease, and PXR antagonists have recently been considered as a therapy for colon cancer.

Antagonizing the action of the human nuclear xenobiotic receptor PXR may have important clinical implications in preventing drug-drug interactions and improving therapeutic efficacy. Evidence has been provided that the naturally occurring phytoestrogen coumestrol is an antagonist of the nuclear receptor PXR (NR1I2). In transient transfection assays, coumestrol was able to suppress the agonist effects of SR12813 on human PXR activity. PXR activity was assessed and correlated with effects on the metabolism of the anesthetic tribromoethanol and on gene expression in primary human hepatocytes. Coumestrol was found to suppress the effects of PXR agonists on the expression of the known PXR target genes CYP3A4 and CYP2B6 in primary human hepatocytes, as well as inhibit metabolism of tribromoethanol in humanized PXR mice.

The relationship between coumestrol dimethyl ether and PXR is distinct from that of the parent compound. When the related compounds coumestrol diacetate and coumestrol dimethyl ether were tested, both analogs increased the basal expression of the reporter by approximately 100 and 120%, respectively; however, the analogs did not antagonize PCN-mediated activation of PXR. This finding indicates that, unlike coumestrol, the dimethyl ether analog does not function as a PXR antagonist; instead it appears to act as a weak agonist or activator of basal PXR reporter expression. Studies have shown that coumestrol dimethyl ether, unlike its parent compound coumestrol, lacks the crucial hydroxyl groups needed for PXR activation in the antagonist mode. Instead, it has been described as potentially preventing PXR activation by other ligands, though its precise role remains under investigation.

Other PXR-related research has shown that coumestrol binds to both the ligand-binding pocket (LBP) and the AF-2 domain of PXR. Computational pharmacophore and docking analyses have confirmed that the known PXR antagonists coumestrol and sulforaphane accommodate the AF-2 ligand-binding site.

GnRH Pathway and Neuroendocrine Effects

Research on the parent compound coumestrol has illuminated neuroendocrine mechanisms relevant to the class. Phytoestrogens can produce inhibitory effects on gonadotropin secretion in both animals and humans, although little is known about the mechanisms and the role of direct action on estrogen receptors in this process. Examination of the effect of coumestrol on gonadotropin-releasing hormone (GnRH) mRNA expression in GT1-7 cells found that coumestrol had an inhibitory effect compared to controls, which was blocked by R,R-THC, a selective ERβ antagonist, suggesting that ERβ is involved in the suppression of GnRH mRNA expression by coumestrol.

Scientific Evidence by Area of Use

Important note on evidence characterization: The overwhelming majority of published research on coumestrol dimethyl ether is preclinical (in vitro, cell-based, or computational). No published clinical trials specifically examining coumestrol dimethyl ether as a dietary supplement or therapeutic agent in humans have been identified in the peer-reviewed literature. Evidence for the biological activities of the compound is therefore limited to laboratory studies, and extrapolation to human health outcomes must be treated with caution. Where human evidence exists for the parent compound coumestrol, this is indicated separately.

1. Estrogen Receptor Biology and Estrogenic Activity

In vitro / biochemical evidence (coumestrol dimethyl ether): Coumestrol dimethyl ether is utilized in research studies to understand the impact of structural modifications on the binding affinity and selectivity of compounds to estrogen receptors. Because both hydroxyl groups required for high-affinity ER binding are methylated, the compound serves primarily as a negative-control or structural comparator in estrogen receptor assays, rather than as an estrogenic agent itself.

In vitro evidence (coumestrol): Coumestrol has been studied as an inherently fluorescent analog of 17β-estradiol by examining its binding to the human estrogen receptor (hER) in extracts of transfected cultured cells. The binding and dissociation can be directly determined by the change in fluorescence intensity. Coumestrol binds to the hER with a ten-fold lower affinity than 17β-estradiol; however, the rate of dissociation appears to be close to that of the native ligand.

Coumestrol competed with 17β-[³H]estradiol for binding to cytoplasmic estrogen receptors, caused cytoplasmic estrogen receptors to associate with chromatin in the nucleus, and induced progesterone receptors.

In vivo animal evidence (coumestrol): In vivo studies with ovariectomized (OVX) rats demonstrated that coumestrol prevented bone loss, lowered cholesterol levels, and increased uterine weight. Investigation of the effects of coumestrol in OVX mice fed a high-fat diet compared with the effects of 17β-estradiol replacement found that coumestrol administered daily at 5 mg/kg for 10 weeks via the subcutaneous route stimulated uterine growth in OVX mice at a level lower than that of E2. Both E2 and coumestrol prevented body fat accumulation, adipocyte hypertrophy, and hepatic steatosis, and enhanced voluntary physical activity. The metabolic effects of oral coumestrol at 10 mg/kg for 7 weeks were mostly abolished following co-treatment with an ERβ-selective antagonist but not with an ERα-selective antagonist, indicating that the metabolic actions of coumestrol in OVX mice are primarily mediated by ERβ.

Evidence strength: Mechanistic in vitro and animal studies are available for coumestrol; no clinical human studies address coumestrol dimethyl ether specifically as an estrogenic agent. Evidence for direct estrogenic activity of coumestrol dimethyl ether at the molecular level is weak, given its blocked hydroxyl groups.

2. PXR Modulation and Drug Metabolism

In vitro and cell-based evidence (coumestrol): Evidence has been provided that coumestrol is an antagonist of the nuclear receptor PXR (NR1I2). In transient transfection assays, coumestrol was able to suppress the agonist effects of SR12813 on human PXR activity. Coumestrol was found to suppress the effects of PXR agonists on the expression of CYP3A4 and CYP2B6 in primary human hepatocytes, and inhibit metabolism of tribromoethanol in humanized PXR mice. At concentrations above 1.0 μM, coumestrol competed in scintillation proximity assays with a labeled PXR agonist for binding to the ligand-binding cavity.

In vitro evidence (coumestrol dimethyl ether specifically): When coumestrol dimethyl ether was tested alongside coumestrol diacetate, both analogs increased basal expression of the PXR reporter by 100 and 120%, respectively, but did not antagonize PCN-mediated activation of PXR. This is a critical finding: the dimethyl ether does not replicate the PXR antagonism of the parent compound.

Evidence strength: Preclinical only. PXR antagonism by coumestrol has been demonstrated in cell and humanized mouse models; coumestrol dimethyl ether lacks this activity. No clinical studies exist. Phytochemicals including coumestrol display weak potency in repressing PXR function. There are currently no PXR antagonists that can be used in a clinical setting.

3. Bone Health and Osteoporosis

Animal evidence (coumestrol): In vivo studies with OVX rats demonstrated that coumestrol prevented bone loss and lowered cholesterol levels. Tentative evidence from dietary intervention studies suggests phytoestrogens may have similar effects in maintaining bone density to those of the related pharmaceutical compound ipriflavone.

Evidence strength for coumestrol dimethyl ether: No studies specifically addressing coumestrol dimethyl ether and bone health have been identified. The anti-osteoporotic effects observed in animal models are attributed to the ER-agonist activity of coumestrol, mediated through its free hydroxyl groups — groups that are blocked in the dimethyl ether. These findings cannot be directly extrapolated.

4. Antioxidant Activity

Mechanistic evidence (coumestrol dimethyl ether): Coumestrol exhibits high antioxidant activity via hydrogen atom transfer (HAT) from its –OH groups. In coumestrol dimethyl ether, the methylation of the 7,12-hydroxyls blocks this HAT mechanism, so CDE will likely show negligible activity in cell-free assays such as DPPH or ABTS. If activity is observed, it indicates either sample impurity (residual coumestrol) or a single electron transfer (SET) mechanism stabilized by the conjugated system.

Studies suggest coumestrol dimethyl ether may possess some antioxidant properties; however, further research is needed to understand its potential health benefits and mechanisms of action.

Evidence strength: Very preliminary. The structural modifications in coumestrol dimethyl ether are expected to substantially reduce direct antioxidant activity compared with coumestrol. No clinical evidence exists.

5. Metabolic Syndrome, Obesity, and Diabetes

Research on the parent compound coumestrol has explored metabolic effects. E2 and coumestrol prevented body fat accumulation, adipocyte hypertrophy, and hepatic steatosis, and enhanced voluntary physical activity in OVX mice. Compositions comprising coumestrol or bean extracts containing coumestrol have been investigated as potential compositions for inhibiting differentiation of adipocytes. Coumestrol inhibits differentiation of adipocytes and decreases mRNA expression of molecular markers of adipocyte differentiation and fatty acid synthesis.

Research has associated plasma phytoestrogens, including coumestrol, with a lower risk of developing metabolic syndrome. However, the phytoestrogens measured in plasma could be considered as biomarkers of a vegetable-based diet, which is known to reduce the risk of metabolic syndrome independently.

Evidence strength for coumestrol dimethyl ether: No studies exist. Effects observed for coumestrol depend on ER-mediated and other mechanisms that may be fundamentally altered by O-methylation.

6. Cancer Biology

Evidence (coumestrol): Coumestrol and other phytoestrogens have been investigated as a possible substitute for hormone therapy and chemotherapy in breast cancer patients. The results of various studies regarding the use of phytoestrogens in treating breast cancer have been somewhat contradictory and ambiguous, and as a result, researchers cannot clearly define phytoestrogens like coumestrol as being chemoprotective agents or as potentially having negative effects, such as inducing further growth of existing breast cancer tumors by activating ERα receptors.

Researchers at Georgetown University Medical Center have investigated this matter and concluded that phytoestrogens may be used as an effective treatment for breast cancer because of their apoptotic properties, but that it is only safe to do so after menopause, when women have a much lower level of estrogen in their bodies, or when used conjunctively with anti-estrogen therapies.

Evidence strength for coumestrol dimethyl ether: No cancer-specific studies for the dimethyl ether exist. Because its estrogenic activity is expected to be substantially reduced by O-methylation, the dual risks and potential benefits associated with ER-mediated effects in cancer are less directly applicable.

7. Fluorescence-Based Research Tools (Primary Demonstrated Use)

The most established and directly verified application of coumestrol dimethyl ether — and of coumestrol itself — is as a research tool exploiting intrinsic fluorescence. Estrogen receptor (ER) is a ligand-inducible transcriptional factor involving in cell growth, differentiation, and diseases; detection and identification of compounds with estrogenic effects are of great importance in the drug discovery industry. A rapid, simple, and homogeneous method for detecting estrogenic compounds has been developed and validated using fluorescence polarization (FP) with the autofluorescent phytoestrogen coumestrol. Coumestrol dimethyl ether is widely used in biochemical assays and fluorescence studies due to its fluorescent properties. It can also be used in studies investigating the role of plant secondary metabolites in plant ecology and interactions with herbivores or pathogens.

More recently, a FRET-based competitive binding assay using coumestrol and the ligand-binding domain of human estrogen receptor alpha has been developed for screening applications.

Body Systems and Health Areas of Association

Endocrine / Reproductive System: Because coumestrol is an estrogen mimic, it is an endocrine disruptor with the potential to affect all organ systems that are regulated hormonally via estrogens. The dimethyl ether's reduced ER affinity is expected to substantially diminish this concern relative to the parent compound, but has not been systematically tested.
Hepatic (Liver) System: PXR regulates the expression of drug-metabolizing enzymes and transporters to control the degradation and excretion of endobiotics and xenobiotics, including therapeutic agents. The metabolism and disposition of drugs might compromise their efficacy and possibly cause drug toxicity and/or drug resistance. Coumestrol dimethyl ether's observed induction of basal PXR reporter expression is relevant to hepatic drug metabolism pathways.
Skeletal System: Bone health associations are documented for coumestrol via ER-mediated mechanisms; coumestrol dimethyl ether has not been independently evaluated.
Cardiovascular System: Health benefits including a lowered risk of heart disease are frequently attributed to phytoestrogens in general. No direct studies on the dimethyl ether and cardiovascular outcomes exist.
Neuroendocrine System: The parent compound has been demonstrated to modulate GnRH expression via ERβ. The dimethyl ether's relevance to this pathway is uncharacterized.

Dosage Forms and Reported Dosages

Coumestrol dimethyl ether has not been subject to clinical dose-finding, pharmacokinetic, or therapeutic human trials. The compound is commercially available solely as a laboratory-grade reagent. No dosages for human use appear in peer-reviewed literature for this specific compound.

For reference, dosages reported for the parent compound coumestrol in published animal studies include:

Subcutaneous or oral treatment of OVX mice at a dose of 5 mg/kg per day for 10 weeks in a metabolic dysfunction study.
Oral administration at 10 mg/kg for 7 weeks in OVX mice to assess ER-mediated metabolic effects.
Neonatal male rats injected with 100 micrograms of coumestrol or vehicle (DMSO) daily during their first 5 days of life, with endpoints assessed at day 60.
A single neonatal injection of 3 mg coumestrol was effective in suppressing ovulation-inducing mechanisms and lordosis induction in female rats, while 1 mg was effective only on the estrous cycle.

These dosages are cited for scientific context only and do not constitute any recommendation for human use of coumestrol dimethyl ether or coumestrol.

Safety Considerations and Interactions

Genotoxicity of the Parent Compound

Coumestrol, a phytoestrogen found in high levels in alfalfa and red clover, is of concern since endocrine disorders have been observed in farm animals exposed to high levels of phytoestrogens. Previous studies found that coumestrol was an effective inducer of DNA strand breaks, micronuclei, and mutations in the Hypoxanthine phosphoribosyl transferase (HPRT) gene of Chinese hamster ovary cells. Subsequent examination of coumestrol exposure in AHH-1 TK(+/-) human lymphoblastoid cells found that micronuclei were induced with the highest frequency occurring at day 2 after exposure. Flow cytometric analysis indicated that the primary pathway of cell death was by apoptosis. Mutations were induced in the Thymidine Kinase (TK) gene due primarily to the induction of clones with the slow-growth phenotype. Molecular analysis revealed the loss of exon 4 in the coumestrol-induced clones, indicative of loss of heterozygosity and consistent with a proposed inhibition of topoisomerase-II activity. Taken together, these results suggest that coumestrol exhibits both mutagenic and clastogenic properties in cultured human lymphoblastoid cells.

Whether these genotoxic effects are relevant to coumestrol dimethyl ether is unknown, as the hydroxyl groups implicated in some reactive mechanisms are blocked in the dimethyl ether. This has not been directly tested.

Endocrine Disruption Potential

As weak estrogen agonists/antagonists with molecular and cellular properties similar to synthetic endocrine disruptors such as Bisphenol A (BPA), phytoestrogens provide a useful model to comprehensively investigate the biological impact of endocrine disruptors in general. Coumestrol and other phytoestrogens have been shown to affect sexual behavior in rats by antagonizing the action of estrogen within the brain; male rats that nursed from females with coumestrol in their diets were less likely to mount a female rat and less likely to ejaculate, despite producing normal levels of testosterone. Exposure produced similar decreases of sexual behavior in female rats, as a result of disruption of estrogen-dependent gene expression in the brain.

There is hardly any data on the effect of coumestrol on human reproduction because common exposure is low, and when correlation of reproductive parameters was attempted with coumestrol in biological fluids, it was not significant. Conversely, in animals, many effects were recorded in rats after plausible dietary administration.

Interaction with Drug-Metabolizing Enzymes (Drug Interactions)

Coumestrol was able to suppress the effects of PXR agonists on the expression of the known PXR target genes CYP3A4 and CYP2B6 in primary human hepatocytes. CYP3A4 is the most abundant drug-metabolizing enzyme in the human liver and intestine, responsible for the metabolism of approximately half of all clinically used drugs. Suppression of PXR-mediated CYP3A4 induction could theoretically reduce the clearance of co-administered drugs metabolized by this enzyme. As noted above, coumestrol dimethyl ether does not appear to replicate this PXR antagonism, but its induction of basal PXR reporter activity by approximately 120% raises separate questions about its influence on drug metabolism pathways that remain uninvestigated in human systems.

PXR is a nuclear receptor protein involved in regulating drug metabolism and disposition. PXR activation by certain drugs can lead to drug-drug interactions, where one drug can interfere with the metabolism of another, impacting its efficacy or causing adverse effects.

Reproductive and Developmental Safety Concerns (Parent Compound)

Concerns remain regarding the safety of dietary phytoestrogens at higher doses, particularly in hormone-sensitive conditions. The question of whether phytoestrogens are beneficial or harmful to human health remains unresolved. The answer is likely complex and may depend on age, health status, and even the presence or absence of specific gut microflora. Although the exact amount of coumestrol the average person consumes has not been calculated, studies of phytoestrogen intake suggest that most human diets result in a negligible intake of coumestrol relative to the maximum tolerable daily intake.

Regulatory and Classification Status

Coumestrol dimethyl ether is not registered with any major regulatory body (FDA, EMA, EFSA) as an approved supplement ingredient or drug. It is classified exclusively as a laboratory research reagent. It is supplied for research use only, and is not intended for diagnostic or therapeutic use. No monographs in the European Pharmacopoeia, USP, WHO monograph series, ESCOP, or German Commission E have been identified for this compound.

Summary of Evidence Status

Coumestrol dimethyl ether is a naturally occurring O-methylated coumestan isolated from Dalbergia decipularis and Bobgunnia madagascariensis. Its primary established applications are as a fluorescent biochemical research tool and as a structural analog/comparator in studies of coumestrol and related phytoestrogens. The compound has been tested in cell-based assays for PXR modulation, where it was found to differ fundamentally from its parent compound by failing to antagonize PXR. No human clinical trials have been conducted with coumestrol dimethyl ether. The broader body of coumestrol research — encompassing animal studies on bone health, metabolic disorders, and estrogenic activity — cannot be directly applied to the dimethyl ether given the structural importance of the hydroxyl groups that are blocked in this derivative. All statements of potential health benefit for this compound as a dietary supplement currently lack clinical evidence and should be regarded as unproven.

References

Health Conditions

Health conditions that Coumestrol dimethyl ether may help support.

No conditions available.

Body Systems

Body systems that Coumestrol dimethyl ether may help support.

No body systems available.